|  |
 |
 |
 |
 |
| Insurance Fears Lead Many to Shun DNA Testsby Amy Harmon, New York TimesFebruary 24th, 2008The first, much-anticipated benefits of personalized medicine are being lost or diluted for many Americans who are too afraid that genetic information may be used against them to take advantage of its growing availability. |
| Goozner: Inaction on Institutional Conflicts of Interestby Jesse Reynolds, Biopolitical TimesFebruary 13th, 2008Not only have less than two in five US medical schools implemented recommended policies governing institutional conflicts of interest, but those recommendations don't address conflicts on the Institutional Review Boards that offer ethical approval for research involving human subjects. |
| Warning: Side Effects May Include Cynicismby Marcy Darnovsky, Biopolitical TimesFebruary 13th, 2008Big Pharma is lobbying hard to get the European Union to permit direct-to-consumer marketing of prescription drugs. Consumer groups are pushing back with spoofs of drug ads. |
| Geron's Steadfast Optimismby Jesse Reynolds, Biopolitical TimesFebruary 12th, 2008Does Okarma really believe that the feds will so quickly turn around the first application for human testing of an entirely new method of medicine? |
| Cloning Critics Split [PDF][Quotes CGS's Richard Hayes]by Neil Munro, National JournalFebruary 2nd, 2008Concern about cloning animals doesn't overlap with stances on human cloning. |
| What to Expect in ’08: Stem Cell Researchby Jesse Reynolds, Biopolitical TimesJanuary 19th, 2008Prognostication is a risky endeavor, but we can't resist making a few general predictions about the world of stem cell research. |
| Update: Mooney on the Office of Technology Assessmentby Jesse Reynolds, Biopolitical TimesJanuary 14th, 2008A couple months ago, I wrote about presidential candidate Senator Hillary Clinton and her reference to reviving the Office of Technology Assessment. Chris Mooney provides an update for the Center for American Progress, and his outlook is not optimistic. |
| A Double Standard for Stem Cells and PGDby Jesse Reynolds, Biopolitical TimesJanuary 11th, 2008The logic behind the rejection by the National Institutes of Health for the funding of ACT's new stem cell method is both revealing and perplexing. |
|
|
 |
 |
 |
 |
| |
|
Highlighted Topics
